Bridgeway Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Bridgeway Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-64,600	Closed	-$117K	–	1461
2023 Q2	$117K	Sell	64,600 -147,900	-70%	-$270K	﹤0.01%	1234
2023 Q1	$281K	Hold	212,500	–	–	0.01%	1032
2022 Q4	$359K	Hold	212,500	–	–	0.01%	951
2022 Q3	$393K	Buy	+212,500	New	+$634K	0.01%	957

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bridgeway Capital Management's PRDS Position: Q3 2023 in Review

Bridgeway Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 64,600 shares — an estimated $117K sold.

Bridgeway Capital Management first reported a position in PRDS in Q3 2022 and held it in 4 quarters. The position peaked at $393K in Q3 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Bridgeway Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Bridgeway Capital Management sold 64,600 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $117K.
Bridgeway Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
Bridgeway Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $393K in Q3 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Bridgeway Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.